Other Events ·
NeuroSense files U.S. patent application for PrimeC to treat traumatic brain injury
NRSNNeuroSense Therapeutics Ltd.
NeuroSense Therapeutics filed a U.S. patent application covering methods of treating traumatic brain injury (TBI) and related central nervous system injuries using its lead drug candidate, PrimeC. The application covers concussion, blast-related injury, and chronic traumatic encephalopathy (CTE), with potential protection through 2047 if granted. This filing supports the company's strategy to expand PrimeC beyond its primary ALS development program into a broader neurological market lacking approved disease-modifying therapies. NeuroSense Therapeutics is a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases.